XML 155 R141.htm IDEA: XBRL DOCUMENT v3.20.2

Stock-Based Compensation (Details Narrative) (Brooklyn ImmunoTherapeutics, LLC) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Stock-based compensation	$ 43,000	$ 50,000	$ 82,000	$ 109,000	$ 206,000	$ 443,000
Brooklyn Immunotherapeutics, LLC [Member]
Stock-based compensation			$ 45,468	$ 45,744

X

- Definition

Amount of noncash expense for share-based payment arrangement.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

+ Details

Name:	us-gaap_ShareBasedCompensation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Details

Name:	srt_ConsolidatedEntitiesAxis=NTN_BrooklynImmunotherpeuticsLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: